Inhibrx Biosciences, Inc. financial data

Symbol
INBX on Nasdaq
Location
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 497 %
Debt-to-equity 44.5 %
Return On Equity 1.1K %
Return On Assets 762 %
Operating Margin -150K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.5M shares
Common Stock, Shares, Outstanding 14.5M shares
Entity Public Float 169M USD
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 15.5M shares +13.4%
Weighted Average Number of Shares Outstanding, Diluted 15.5M shares +13.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 200K USD
Research and Development Expense 177M USD -42.2%
General and Administrative Expense 124M USD -39.6%
Operating Income (Loss) -301M USD +41.9%
Nonoperating Income (Expense) 2.02B USD +91.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43.3M USD +45%
Income Tax Expense (Benefit) 2K USD
Net Income (Loss) Attributable to Parent 1.72B USD +45%
Earnings Per Share, Basic 117 USD/shares +51.5%
Earnings Per Share, Diluted 116 USD/shares +51.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 217M USD
Other Assets, Current 269K USD
Assets, Current 223M USD
Property, Plant and Equipment, Net 5.55M USD
Operating Lease, Right-of-Use Asset 6.9M USD
Other Assets, Noncurrent 6.8M USD
Assets 243M USD
Accounts Payable, Current 8.89M USD
Employee-related Liabilities, Current 2.72M USD
Accrued Liabilities, Current 32.8M USD
Liabilities, Current 43.6M USD
Operating Lease, Liability, Noncurrent 5.9M USD
Liabilities 148M USD
Retained Earnings (Accumulated Deficit) -149M USD
Stockholders' Equity Attributable to Parent 94.4M USD +716%
Liabilities and Equity 243M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -35.9M USD +43.1%
Net Cash Provided by (Used in) Financing Activities 99.8M USD +158%
Net Cash Provided by (Used in) Investing Activities -21K USD +98.1%
Common Stock, Shares Authorized 120M shares
Common Stock, Shares, Issued 14.5M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 63.9M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 217M USD -14.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.3M USD -81.2%
Deferred Tax Assets, Valuation Allowance 21.8M USD -85.1%
Deferred Tax Assets, Gross 24M USD -83.6%
Operating Lease, Liability 7.88M USD
Payments to Acquire Property, Plant, and Equipment 21K USD -98.1%
Lessee, Operating Lease, Liability, to be Paid 9.26M USD
Property, Plant and Equipment, Gross 15.1M USD
Operating Lease, Liability, Current 1.97M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.94M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.86M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.38M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.49M USD
Deferred Tax Assets, Operating Loss Carryforwards 4.73M USD -93.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares
Unrecognized Tax Benefits 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.49M USD
Additional Paid in Capital 244M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.6M USD +87.5%
Deferred Tax Assets, Net of Valuation Allowance 2.19M USD +233%
Share-based Payment Arrangement, Expense 1.8M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares